Figure 1: Cancer stem-like cells (CSCs) undergo two types of cell division....
Figure 1: Cancer stem-like cells (CSCs) undergo two types of cell division. CSCs can self-renew and differentiate. Two types of cell division can occur: symmetric or asymmetric. In the former, two self-renewing CSCs are generated; in the latter, only one (and a differentiated cell).

Source: Kanazawa University

News • Cancer stem-like cells

Important signaling pathway in breast cancer revealed

In breast cancer, one of the most common cancers in women, tumors contain a small amount of so-called cancer stem-like cells (CSCs). Being able to eliminate breast-cancer stem-like cells in a targeted way is essential for developing successful therapies.

Conventional treatments, such as chemotherapy or radiotherapy followed by drug intake, do not target CSCs. A better understanding of the processes generating CSCs in breast-cancer tumors is needed. Noriko Gotoh from Kanazawa University and colleagues have now uncovered a signaling pathway directly related to the proliferation of CSCs in breast cancer. Their findings have now been published in the journal Proceedings of National Academy of Science of the United States of America (PNAS).

A property of stem cells is that they can self-renew and differentiate. Two types of stem-cell division can occur: symmetric or asymmetric (Fig. 1 above). In the former, two self-renewing stem cells are generated; in the latter, only one (and a differentiated cell). It is now believed that malignant CSCs have a higher tendency to divide symmetrically, thus increasing the number of CSCs. Gotoh and colleagues looked at how the microenvironment of CSCs, called the CSC niche, causes and sustains an increased rate of symmetric division.

Photo
Figure 2: Semaphorin 3 (Sema3) produced by differentiated cancer cells in CSC niche affects CSCs. CSC niche contains various kinds of cells, including CSCs, differentiated cancer cells. endothelial cells in blood vessels, and immune cells. Sema3 is mainly produced by differentiated cancer cells in CSC niche.
Source: Kanazawa University

The researchers started from the observation that a particular gene encoding a type of cytokine known as Semaphorin 3 (Sema3) was one of the most-expressed genes in the CSC niche (Fig. 2). (Cytokines are small proteins that, when released, affect the behavior of cells around them.) The production of Sema3 activates another protein, called MICAL3, the expression levels of which were also found to be high in the CSC niche. Via a series of experiments in vitro, Gotoh and colleagues were able to confirm the critical roles of Sema3 and MICAL3 in breast cancer tumor development. Specifically, MICAL3 was shown to be required for tumor sphere formation (tumorigenicity is associated with spherical cell shapes). The scientists showed that Sema3-stimulated MICAL3 triggered a whole sequence of biomolecular interactions (a signaling pathway), ultimately resulting in induced symmetric division of CSCs, and hence their proliferation, in breast cancer (Fig. 3).

Photo
Figure 3: Sema3 activates MICAL3 in breast CSCs and induces symmetric division of CSCs, leading to expand CSCs. MICAL3 is a targetable molecule to reduce CSCs.
Source: Kanazawa University

Having established this important pathway is highly relevant for developing treatments for breast cancer, because, quoting Gotoh and colleagues, “by inhibition of MICAL3 … or knockdown of each component in the signaling pathway, the symmetric cell division may be inhibited, leading to a reduction of breast-cancer stem-like cells.”


Source: Kanazawa University

28.01.2019

Read all latest stories

Related articles

Photo

News • Making tumours susceptible to chemo

Breast cancer: target protein may hold key to therapy success

A rare variant of a protein present in nearly all human cells may hold the key to improving the effectiveness of breast cancer treatment, according to University of Manchester research.  

Photo

News • Patient-derived whole-tumor cell culture model

Breast cancer: New method finds the right therapy

Swedish researchers have developed a method that should be able to predict whether a patient with breast cancer will benefit from a particular treatment or not.

Photo

News • Filopodia research

'Sticky fingers' in cells keep breast cancer contained

Researchers in Finland have identified that finger-like cellular extensions called filopodia contribute to building a barrier surrounding breast tumours.

Related products

3DQuorum SmartSlices

Artificial Intelligence

Hologic · 3DQuorum SmartSlices

Hologic, Inc.
50° wide-angle Tomosynthesis

Tomosynthesis

Siemens Healthcare · 50° wide-angle Tomosynthesis

Siemens Healthcare GmbH
Advanced Breast-CT - nu:view

Mammo CT

AB-CT · Advanced Breast-CT - nu:view

AB-CT – Advanced Breast-CT GmbH
Aidia

Digital Mammography

Drtech Europe · Aidia

DRTECH EUROPE GmbH
Subscribe to Newsletter